RAMAT GAN, Israel — November 24, 2025 — Leads & Copy — Can-Fite BioPharma Ltd. will participate in BioFIT 2025, a life sciences conference held in Strasbourg, France, on December 2–3, 2025.
The biotechnology company (NYSE American: CANF) (TASE: CANF) is focused on advancing a pipeline of small molecule drugs for oncological and inflammatory diseases. The conference brings together academia, industry, and investors to facilitate technology transfer, early-stage collaborations, and investment in biotech and medtech.
Can-Fite BioPharma is seeking a second veterinary partnership focused on Namodenoson, its Phase III anti-cancer drug candidate, at BioFIT 2025.
According to Can-Fite’s VP of Business Development Dr. Sari Fishman, its previous participation at BioFIT led directly to its successful partnership with Vetbiolix for Piclidenoson to treat osteoarthritis in dogs and cats. That agreement is potentially worth an estimated $325 million in royalty revenues for Can-Fite.
Namodenoson has demonstrated strong anti-tumor activity, a complete response in a human liver cancer patient, and an excellent safety profile, making it a compelling candidate for veterinary oncology.
Namodenoson is currently being evaluated in human clinical trials including a Phase III liver cancer trial and Phase II pancreatic cancer study. The veterinary oncology market is projected to reach $3.1 billion by 2030.
Can-Fite is also developing Piclidenoson for treating osteoarthritis in pets. Clinical studies show efficacy in dogs, representing a $3 billion market.
The company will hold partnering meetings with major multinational animal health companies, including Elanco Animal Health and Zoetis, during the conference to explore collaboration opportunities for bringing Namodenoson into veterinary development.
Can-Fite’s lead drug candidate, Piclidenoson reported topline results in a Phase III trial for psoriasis and commenced a pivotal Phase III trial. Can-Fite’s liver drug, Namodenoson, is being evaluated in a Phase III trial for hepatocellular carcinoma (HCC), a Phase IIb trial for the treatment of MASH, and in a Phase IIa study in pancreatic cancer.
Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company’s third drug candidate, has shown efficacy in the treatment of erectile dysfunction.
These drugs have an excellent safety profile with experience in over 1,600 patients in clinical studies to date.
Contact:
Can-Fite BioPharma
Motti Farbstein
info@canfite.com
+972-3-9241114
Source: Can-Fite BioPharma Ltd.
